Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ampicillin-resistant and vancomycin-susceptible Enterococcus faecium bacteremia: a clinical narrative review.
Echeverria-Esnal D, Sorli L, Navarrete-Rouco ME, Prim N, Barcelo-Vidal J, Conde-Estévez D, Montero MM, Martin-Ontiyuelo C, Horcajada JP, Grau S. Echeverria-Esnal D, et al. Among authors: horcajada jp. Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):759-775. doi: 10.1080/14787210.2023.2223977. Epub 2023 Jun 14. Expert Rev Anti Infect Ther. 2023. PMID: 37294450 Review.
Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa: In Vivo and In Vitro Evidence.
Lopez-Montesinos I, Montero MM, Domene-Ochoa S, López-Causapé C, Echeverria D, Sorlí L, Campillo N, Luque S, Padilla E, Prim N, Grau S, Oliver A, Horcajada JP. Lopez-Montesinos I, et al. Among authors: horcajada jp. Antibiotics (Basel). 2022 Oct 22;11(11):1456. doi: 10.3390/antibiotics11111456. Antibiotics (Basel). 2022. PMID: 36358110 Free PMC article.
Real-world experience of therapeutic drug monitoring and PK/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria.
Fresán D, Luque S, Benítez-Cano A, Sorlí L, Montero MM, De-Antonio M, Vega V, Roberts JA, Horcajada JP, Grau S. Fresán D, et al. Among authors: horcajada jp. J Antimicrob Chemother. 2023 Dec 1;78(12):2810-2815. doi: 10.1093/jac/dkad296. J Antimicrob Chemother. 2023. PMID: 37823445
Safety and efficacy of favipiravir in COVID-19 patients with pneumonia. A randomized, double-blind, placebo-controlled study (FAVID).
Horcajada JP, Aldonza R, Real M, Castañeda-Espinosa S, Sendra E, Gomez-Junyent J, López-Montesinos I, Gómez-Zorrilla S, Briansó S, Duran-Taberna M, Fernández A, Tarragó C, Auguet-Quintillá T; COVID-MAR Research group; COVID-HJ23 group. Horcajada JP, et al. Pneumonia (Nathan). 2024 Feb 25;16(1):3. doi: 10.1186/s41479-023-00124-6. Pneumonia (Nathan). 2024. PMID: 38402214 Free PMC article.
Antimicrobial stewardship in hospitals: Expert recommendation guidance document for activities in specific populations, syndromes and other aspects (PROA-2) from SEIMC, SEFH, SEMPSPGS, SEMICYUC and SEIP.
Cercenado E, Rodríguez-Baño J, Alfonso JL, Calbo E, Escosa L, Fernández-Polo A, García-Rodríguez J, Garnacho J, Gil-Navarro MV, Grau S, Gudiol C, Horcajada JP, Larrosa N, Martínez C, Molina J, Nuvials X, Oliver A, Paño-Pardo JR, Pérez-Rodríguez MT, Ramírez P, Rey-Biel P, Vidal P, Retamar-Gentil P. Cercenado E, et al. Among authors: horcajada jp. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Apr;41(4):238-242. doi: 10.1016/j.eimce.2022.05.013. Epub 2023 Jan 5. Enferm Infecc Microbiol Clin (Engl Ed). 2023. PMID: 36610836 Review.
In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review.
Aslan AT, Ezure Y, Horcajada JP, Harris PNA, Paterson DL. Aslan AT, et al. Among authors: horcajada jp. Front Med (Lausanne). 2023 Sep 4;10:1249030. doi: 10.3389/fmed.2023.1249030. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37727767 Free PMC article.
Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis.
Sastre-Femenia MÀ, Fernández-Muñoz A, Gomis-Font MA, Taltavull B, López-Causapé C, Arca-Suárez J, Martínez-Martínez L, Cantón R, Larrosa N, Oteo-Iglesias J, Zamorano L, Oliver A; GEMARA-SEIMC/CIBERINFEC Pseudomonas study Group. Sastre-Femenia MÀ, et al. Lancet Reg Health Eur. 2023 Sep 19;34:100736. doi: 10.1016/j.lanepe.2023.100736. eCollection 2023 Nov. Lancet Reg Health Eur. 2023. PMID: 37753216 Free PMC article.
338 results